Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16
Bicara Therapeutics Inc.
Bicara Therapeutics Inc. BCAX | 0.00 |
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:
BCAX) with a Equal-Weight and raises the price target from $11 to $16.
